Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

November 30, 2006

Conditions
Venous ThromboembolismBrain Tumors
Interventions
DRUG

dalteparin

Trial Locations (14)

2217

The St. George Hospital, Kogarah

6009

Sir Charles Gairdner Hospital, Nedlands

6847

Royal Perth Hospital, Perth

24128

Ospedali Riuniti di Bergamo, Bergamo

48202

Henry Ford Hospital, Detroit

60201

Kellogg Cancer Center - Evanston Northwestern Healthcare, Evanston

84112-5550

Huntsman Cancer Institute, Salt Lake City

T6G 1Z2

Cross Cancer Institute, Edmonton

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

Nova Scotia Cancer Centre, Halifax

K1H 8L6

The Ottawa Hospital Regional Cancer Centre, Ottawa

M4N 3M5

Toronto-Sunnybrook Regional Cancer Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

06123

Università di Perugia, Perugia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER

NCT00135876 - Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients | Biotech Hunter | Biotech Hunter